EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: How do we interpret the clinical and biomarker data?

Raffaele Califano, Fiona H. Blackhall, Giovanna Finocchiaro, Luca Toschi, Nicholas Thatcher, Federico Cappuzzo, Lucio Crinò

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The clinical development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for treatment of non-small cell lung cancer (NSCLC) is a major breakthrough in the field. Erlotinib is the first of this class of drug demonstrated in a placebo-controlled trial to prolong survival of patients with previously treated NSCLC. The challenge now is how best to select patients for this treatment. Clinical factors including female gender, East Asian ethnic origin, adenocarcinoma histology, and a history of never-smoking are associated with better response rates, but response to erlotinib is not exclusive to these populations or essential for a survival benefit. Molecular factors such as EGFR mutation and increased EGFR gene copy number provide objective tests that may be superior to clinical factors for patient selection, but assay for these factors is crucially dependent on available tumor tissue and to date, there are no published data from randomized trials where tumor tissue is available from all patients. Here we review the clinical and biological factors that may be applied to select patients for treatment with EGFR-TKIs and conclude that the available data are premature for definitive guidelines to select against an EGFR-TKI.

Original languageEnglish
Pages (from-to)173-186
Number of pages14
JournalTargeted Oncology
Volume3
Issue number3
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Biomarkers
Epidermal Growth Factor Receptor
erbB-1 Genes
Gene Dosage
Survival
Biological Factors
Patient Selection
Neoplasms
Histology
Adenocarcinoma
Therapeutics
Smoking
Placebos
Guidelines
Mutation
Pharmaceutical Preparations
Population
Erlotinib Hydrochloride

Keywords

  • EGFR
  • Erlotinib
  • Gefitinib
  • Non-small cell lung cancer
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients : How do we interpret the clinical and biomarker data? / Califano, Raffaele; Blackhall, Fiona H.; Finocchiaro, Giovanna; Toschi, Luca; Thatcher, Nicholas; Cappuzzo, Federico; Crinò, Lucio.

In: Targeted Oncology, Vol. 3, No. 3, 07.2008, p. 173-186.

Research output: Contribution to journalArticle

Califano, Raffaele ; Blackhall, Fiona H. ; Finocchiaro, Giovanna ; Toschi, Luca ; Thatcher, Nicholas ; Cappuzzo, Federico ; Crinò, Lucio. / EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients : How do we interpret the clinical and biomarker data?. In: Targeted Oncology. 2008 ; Vol. 3, No. 3. pp. 173-186.
@article{554fade3b38b46ebbda62615ff6f2dd4,
title = "EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: How do we interpret the clinical and biomarker data?",
abstract = "The clinical development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for treatment of non-small cell lung cancer (NSCLC) is a major breakthrough in the field. Erlotinib is the first of this class of drug demonstrated in a placebo-controlled trial to prolong survival of patients with previously treated NSCLC. The challenge now is how best to select patients for this treatment. Clinical factors including female gender, East Asian ethnic origin, adenocarcinoma histology, and a history of never-smoking are associated with better response rates, but response to erlotinib is not exclusive to these populations or essential for a survival benefit. Molecular factors such as EGFR mutation and increased EGFR gene copy number provide objective tests that may be superior to clinical factors for patient selection, but assay for these factors is crucially dependent on available tumor tissue and to date, there are no published data from randomized trials where tumor tissue is available from all patients. Here we review the clinical and biological factors that may be applied to select patients for treatment with EGFR-TKIs and conclude that the available data are premature for definitive guidelines to select against an EGFR-TKI.",
keywords = "EGFR, Erlotinib, Gefitinib, Non-small cell lung cancer, Tyrosine kinase inhibitors",
author = "Raffaele Califano and Blackhall, {Fiona H.} and Giovanna Finocchiaro and Luca Toschi and Nicholas Thatcher and Federico Cappuzzo and Lucio Crin{\`o}",
year = "2008",
month = "7",
doi = "10.1007/s11523-008-0084-7",
language = "English",
volume = "3",
pages = "173--186",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients

T2 - How do we interpret the clinical and biomarker data?

AU - Califano, Raffaele

AU - Blackhall, Fiona H.

AU - Finocchiaro, Giovanna

AU - Toschi, Luca

AU - Thatcher, Nicholas

AU - Cappuzzo, Federico

AU - Crinò, Lucio

PY - 2008/7

Y1 - 2008/7

N2 - The clinical development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for treatment of non-small cell lung cancer (NSCLC) is a major breakthrough in the field. Erlotinib is the first of this class of drug demonstrated in a placebo-controlled trial to prolong survival of patients with previously treated NSCLC. The challenge now is how best to select patients for this treatment. Clinical factors including female gender, East Asian ethnic origin, adenocarcinoma histology, and a history of never-smoking are associated with better response rates, but response to erlotinib is not exclusive to these populations or essential for a survival benefit. Molecular factors such as EGFR mutation and increased EGFR gene copy number provide objective tests that may be superior to clinical factors for patient selection, but assay for these factors is crucially dependent on available tumor tissue and to date, there are no published data from randomized trials where tumor tissue is available from all patients. Here we review the clinical and biological factors that may be applied to select patients for treatment with EGFR-TKIs and conclude that the available data are premature for definitive guidelines to select against an EGFR-TKI.

AB - The clinical development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for treatment of non-small cell lung cancer (NSCLC) is a major breakthrough in the field. Erlotinib is the first of this class of drug demonstrated in a placebo-controlled trial to prolong survival of patients with previously treated NSCLC. The challenge now is how best to select patients for this treatment. Clinical factors including female gender, East Asian ethnic origin, adenocarcinoma histology, and a history of never-smoking are associated with better response rates, but response to erlotinib is not exclusive to these populations or essential for a survival benefit. Molecular factors such as EGFR mutation and increased EGFR gene copy number provide objective tests that may be superior to clinical factors for patient selection, but assay for these factors is crucially dependent on available tumor tissue and to date, there are no published data from randomized trials where tumor tissue is available from all patients. Here we review the clinical and biological factors that may be applied to select patients for treatment with EGFR-TKIs and conclude that the available data are premature for definitive guidelines to select against an EGFR-TKI.

KW - EGFR

KW - Erlotinib

KW - Gefitinib

KW - Non-small cell lung cancer

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=49749130422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749130422&partnerID=8YFLogxK

U2 - 10.1007/s11523-008-0084-7

DO - 10.1007/s11523-008-0084-7

M3 - Article

AN - SCOPUS:49749130422

VL - 3

SP - 173

EP - 186

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 3

ER -